Not applicable.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.14744/agri.2021.58751 | DOI Listing |
Background: Intrahepatic cholangiocarcinoma (ICC) presents a significant clinical challenge due to its high fatality rate and limited surgical candidacy. With only 30-40% of patients eligible for surgery upon diagnosis, alternative therapies are imperative. This study assesses the efficacy of Yttrium-90 (Y-90) radioembolization for unresectable ICC patients in a non-university tertiary care center (NUTCC).
View Article and Find Full Text PDFInotuzumab ozogamicin (InO) is approved for treatment of relapsed/refractory acute lymphoblastic leukemia (R/R ALL). Previous studies reported higher rates of post- hematopoietic stem cell transplant (HSCT) hepatic sinusoidal obstruction syndrome (SOS) in patients receiving InO versus chemotherapy prior to HSCT. It is unknown if a lower InO dose would reduce risk of post-HSCT SOS or if it would impact efficacy.
View Article and Find Full Text PDFSpine (Phila Pa 1976)
January 2025
Department of Orthopaedics, All India Institute of Medical Sciences, Rishikesh, India.
Study Design: Systematic review and meta analysis.
Objective: To assess the safety and efficacy of staged versus same-day spinal fusion surgeries in Adult spinal deformity (ASD).
Background: ASD surgeries are associated with high complication rates, ranging from 10% to 40%.
Spine (Phila Pa 1976)
January 2025
Department of Neurological Surgery, Washington University, St. Louis, MO, USA.
Study Design: Prospective cohort study.
Objective: This study aims to define Substantial Clinical Benefit (SCB) thresholds for PROMIS physical function (PF) and pain interference (PI) in lumbar or thoracolumbar spine surgery population.
Summary Of Background Data: Patient-reported outcome measures (PROMs) are widely used in spine surgery to assess treatment efficacy.
Hematology
December 2025
Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, People's Republic of China.
Objective: To evaluate the short-term efficacy and safety of eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in China.
Method: Data were retrospectively collected from patients with PNH who received at least 3 months of full-dose eculizumab. Changes in clinical and laboratory indicators after 1, 3, and 6 months of eculizumab therapy and at the end of follow-up were documented.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!